MEDICINES **OF TOMORROW**



2025 Horizon Scanning Forum | 3 September | Parliament House

Event program

Opening Session Horizon Scanning – The Future is Now	9.15	Welcome and opening remarks	Liz de Somer, CEO, Medicines Australia Penny Shakespeare, Deputy Secretary, Health Resourcing Group, Department of Health, Disability & Ageing
	9.25	Opening address	Blair Comley PSM, Secretary, Department of Health, Disability & Ageing
	9.45	Keynote address Implementation of Horizon Scanning in the international context	Professor Dawn Craig, Director of the NIHR Innovation Observatory at Newcastle University, UK
	10.10	Panel discussion The importance of Horizon Scanning in the Australian context	Led by Dr Orin Chisholm, Associate Professor University of Sydney, who recently received NHMRC funding to establish the Australian Health Innovation Observatory
			Professor Dawn Craig, Director of NIHR Innovation Observatory, UK
			David Pearce, Takeda Managing Director Oceania
			Nicky Conway, Chair, Genetic Alliance Australia
			Jodi Johnson-Glading, Acting ACT Chief Medical Officer Nick Henderson, First Assistant Secretary, Medicines Regulation Division, TGA
	10.30	Audience Q&A	Facilitated by Penny Shakespeare, Deputy Secretary, Health Resourcing Group at Department of Health, Disability & Ageing
	10.50	Morning tea	
Session Two	11.15	Industry showcase	Michelle Gregory, Country Head,
	11.13	madstry snowcase	
Fit for Purpose		•	Public Affairs, Novartis
Regulatory and Reimbursement		Case study – Radioligand therapy	Public Affairs, Novartis Sally Sara, Director of Nursing from Prostate Cancer Foundation
Regulatory and		Case study – Radioligand therapy	Public Affairs, Novartis Sally Sara, Director of Nursing from Prostate Cancer
Regulatory and Reimbursement Pathways for	11.45	Case study – Radioligand therapy Panel discussion	Public Affairs, Novartis Sally Sara, Director of Nursing from Prostate Cancer Foundation Deanna Mill, Evo Health Rodney Hicks, Melbourne Theranostic Innovation Centre
Regulatory and Reimbursement Pathways for Timely Patient	11.45	Case study – Radioligand therapy	Public Affairs, Novartis Sally Sara, Director of Nursing from Prostate Cancer Foundation Deanna Mill, Evo Health
Regulatory and Reimbursement Pathways for Timely Patient	11.45	Case study – Radioligand therapy Panel discussion Fit for purpose regulatory and reimbursement pathways for timely	Public Affairs, Novartis Sally Sara, Director of Nursing from Prostate Cancer Foundation Deanna Mill, Evo Health Rodney Hicks, Melbourne Theranostic Innovation Centre Meredith Cummins, CEO NeuroEndocrine

Session Three The Importance of A Values Framework and Methods for HTA	1.10	Industry showcase	Sharon Weber, Head of Market Access, Takeda
		Case study - small molecule for narcolepsy that targets the mechanism of disease	Dr Aaron Schokman, Lived experience Research Fellow at the University of Sydney and advocate for narcolepsy awareness.
	1.40	Audience Q&A	Facilitated by Liz de Somer, CEO, Medicines Australia
Session Four System Preparedness for Personalised Therapies	1.55	Industry showcase Case study – Personalised mRNA cancer vaccines	Quentin Bracquart, Principal, IQVIA
	2.25	Panel discussion System Preparedness for Personalised Therapies	Led by Penny Shakespeare, Deputy Secretary, Health Resourcing Group, Department of Health, Disability & Ageing
		·	Quentin Bracquart, Principal, IQVIA
			Dr Kaye Robertson, Acting Chief Medical Advisor, TGA
			Professor Matt Brown Chief Scientific Officer, Genomics UK
			Christine Cockburn, CEO of Rare Cancers Australia
	2.45	Audience Q&A	Facilitated by Penny Shakespeare, Deputy Secretary, Health Resourcing Group, Department of Health, Disability & Ageing
Closing Session	3.05	Panel discussion	Led by Dr Orin Chisholm, Associate Professor
Where to From Here? From Conversations to Action	3.03	Where to From Here? From	University of Sydney
		Conversations to Action	Jo Watson, Deputy Chair PBAC and Chair of HTA Consumer Consultative Committee
			Sue MacLeman, Chair of Medicines Australia
			Professor Dawn Craig, Director, NIHR Innovation Observatory
			Clare Stuart, Policy & Advocacy Manager, Mito Foundation
	3:25	Closing remarks	Liz de Somer, CEO, Medicines Australia
		-	Penny Shakespeare, Deputy Secretary, Health Resourcing Group, Department of Health,
			Disability & Ageing